Decreasing incidence of chronic lung disease despite the gradual reduction of postnatal dexamethasone use in very low birth weight infants

Journal of Korean Medical Science

Volumn 19, Issue 4, 2004, Pages 514-518

  Chang, Won Choi ^a   Jong, Hee Hwang ^a   Jae, Won Shim ^b   Sun, Young Ko ^a   Eun, Kyung Lee ^a   Sung, Shin Kim ^c   Yun, Sil Chang ^a   Won, Soon Park ^a   Son, Moon Shin ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Bronchopulmonary Dysplasia; Dexamethasone; Infant; Premature

Indexed keywords

DEXAMETHASONE;

ARTICLE; CHRONIC LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NERVE CELL DIFFERENTIATION; NEWBORN; PERINATAL PERIOD; RETROSPECTIVE STUDY; VERY LOW BIRTH WEIGHT;

EID: 4444367144     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2004.19.4.514     Document Type: Article

References (40)

1. Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983; 1: 1356-8.
2. Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics 1985; 75: 106-11.
3. Grier DG, Halliday HL. Corticosteroids in the prevention and management of bronchopulmonary dysplasia. Semin Neonatol 2003; 8: 83-91.
4. Bhuta T, Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed 1998; 79: F26-33.
5. Arias-Camison JM, Lau J, Cole CH, Frantz ID 3rd. Meta-analysis of dexamethasone therapy started in the first 15 days of life for prevention of chronic lung disease in premature infants. Pediatr Pulmonol 1999; 28: 167-74.
6. Doyle L, Davis P. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. J Paediatr Child Health 2000; 36: 101-7.
7. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; (1): CD001146.
8. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; (1): CD001144.
9. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; (1): CD001145.
10. Soll RF, for the Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease [abstract]. Pediatr Res 1999; 42: 123A.
11. Papile LA, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR, Krause-Steinrauf H, Verter J, Korones SB, Lemons JA, Fanaroff AA, Stevenson DK. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med 1998; 338: 1112-8.
12. Stoll BJ, Temprosa M, Tyson JE, Papile LA, Wright LL, Bauer CR, Donovan EF, Korones SB, Lemons JA, Fanaroff AA, Stevenson Dk, Oh W, Ehrenkranz RA, Shankaran S, Verter J. Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics 1999; 104: e63.
13. Ng PC, Blackburn ME, Brownlee KG, Buckler JM, Dear PR. Adrenal response in very low birthweight babies after dexamethasone treatment for bronchopulmonary dysplasia. Arch Dis Child 1989; 64: 1721-6.
14. Leitch CA, Ahlrichs J, Karn C, Denne SC. Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease. Pediatr Res 1999; 46: 109-13.
15. Berry MA, Abrahamowicz M, Usher RH. Factors associated with growth of extremely premature infants during initial hospitalization. Pediatrics 1997; 100: 640-6.
16. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, Hsieh WS, Lien YJ. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998; 101: E7.
17. Vincer MJ, Allen AC. Double blind controlled trial of 6-day pulse of dexamethasone for very low birth weight infants (VLBWI <1,500 grams) who are ventilator dependent at weeks of age. Pediatr Res 1998; 43: 201A.
18. Kothadia JM, O'Shea TM, Roberts D, Auringer ST, Weaver RG III, Dillard RG. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics 1999; 104: 22-7.
19. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, Yurman S, Dolfin T, Kogan A, Dollberg S, Arbel E, Goldberg M, Gur I, Naor N, Sirota L, Mogilner S, Zaritsky A, Barak M, Gottfried E. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000; 83: F177-81.
20. Sharek PJ, Baker R, Litman F, Kaempf J, Burch K, Schwarz E, Sun S, Payne NR. Evaluation and development of potentially better practices to prevent chronic lung disease and reduce lung injury in neonates. Pediatrics 2003; 111: e426-31.
21. Burch K, Rhine W, Baker R, Litman F, Kaempf JW, Schwarz E, Sun S, Payne NR, Sharek PJ. Implementing potentially better practices to reduce lung injury in neonates. Pediatrics 2003; 111: e432-6.
22. Kaempf JW, Campbell B, Sklar RS, Arduza C, Gallegos R, Zabari M, Brown A, McDonald JV. Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams. Pediatrics 2003; 111: e534-41.
23. Jacobs HC, Chapman RL, Gross I. Premature conclusions on postnatal steroid effects. Pediatrics 2002; 110: 200-1.
24. Burchfield DJ. Postnatal steroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2003; 110: 221-2.
25. Volpe JJ. Neurology of the newborn. 4th Ed. Philadelphia. W.B. Saunders Co., 2001: 451.
26. Salafia CM, Weigl C, Silberman L. The prevalence and distribution of acute placental inflammation in uncomplicated term pregnancies. Obstet Gynecol 1989; 73: 383-9.
27. O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG 3rd, Dillard RG. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999; 104: 15-21.
28. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stell BJ; National Institute of Child Health and Human Development Neonatal Research Network Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001; 344: 95-101.
29. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in pretenn infants. Cochrane Database Syst Rev 2001; (3): CD000503.
30. Tammela OK, Koivisto ME. Fluid restriction for preventing bronchopulmonary dysplasia? Reduced fluid intake during the first weeks of life improves the outcome of low-birth-weight infants. Acta Paediatr 1992; 81: 207-12.
31. Davis P, Jankov R, Doyle L, Henschke P. Randomised, controlled trial of nasal continuous positive airway pressure in the extubation of infants weighing 600 to 1250 g. Arch Dis Child Fetal Neonatal Ed 1998; 79: F54-7.
32. So BH, Tamura M, Mishina J, Watanabe T, Kamoshita S. Application of nasal continuous positive airway pressure to early extubation in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 1995; 72: F191-3.
33. Tapia JL, Bancalari A, Gonzalez A, Mercado ME. Does continuous positive airway pressure (CPAP) during weaning from intermittent mandatory ventilation in very low birth weight infants have risks or benefits? A controlled trial. Pediatr Pulmonol 1995; 19: 269-74.
34. Rebello CM, Ikegami M, Polk DH, Jobe AH. Postnatal lung responses and surfactant function after fetal or maternal corticosteroid treatment. J Appl Physiol 1996; 80: 1674-80.
35. Baud O, Foix-L'Helias L, Kaminski M, Audibert F, Jarreau PH, Papiernik E, Huon C, Lepercq J, Dehan M, Lacaze-Masmonteil T. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999; 341: 1190-6.
36. Shankaran S, Bauer CR, Bain R, Wright LL, Zachary J. Relationship between antenatal steroid administration and grades III and IV intracranial hemorrhage in low birth weight infants. The NICHD Neonatal Research Network. Am J Obstet Gynecol 1995; 173: 305-12.
37. LeFlore JL, Salhab WA, Broyles RS, Engle WD. Association of antenatal and postnatal dexamethasone exposure with outcomes in extremely low birth weight neonates. Pediatrics 2002; 110: 275-9.
38. Jobe AH, Wada N, Berry LM, Ikegami M, Ervin MG. Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep. Am J Obstet Gynecol 1998; 178: 880-5.
39. Jobe AH, Newnham J, Willet K, Sly P, Ikegami M. Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids. Pediatrics 1998; 102: 1116-25.
40. Kim SH, Lee KH, You DK, Lee SH, Shim JW, Chang YS, et al. The incidence and risk factors of bronchopulmonary dysplasia (BPD) in very low birth weight infants. The 52nd Korean Pediatric Annual Meeting Abstract Book 2002; 42.